Assenagon Asset Management
YARW

Assenagon Asset Management’s Yarrow Bioscience YARW Stock Holding History

Assenagon Asset Management’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-18
Closed -$388K – 1088
2019
Q2 		$388K Buy
+18
New +$445K ﹤0.01% 883

Other funds holding YARW

First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Assenagon Asset Management's YARW Position: Q3 2019 in Review

Assenagon Asset Management sold out of Yarrow Bioscience (YARW) in Q3 2019, closing a stake of 18 shares — an estimated $388K sold.

Assenagon Asset Management first reported a position in YARW in Q2 2019 and held it in 1 quarter. The position peaked at $388K in Q2 2019. 48 funds tracked by Wall St. Rank hold YARW as of Q3 2019.

  • Assenagon Asset Management reported no remaining Yarrow Bioscience position as of Q3 2019 after selling out during the quarter.
  • Assenagon Asset Management sold 18 Yarrow Bioscience shares in Q3 2019, an estimated $388K.
  • Assenagon Asset Management first reported a position in Yarrow Bioscience in Q2 2019 and held it in 1 quarter.
  • Assenagon Asset Management's Yarrow Bioscience position peaked at $388K in Q2 2019.
  • 48 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2019.

Based on Assenagon Asset Management's 13F filing for Q3 2019, filed 16 Oct 2019.